Programme SOM0044 for Parkinson’s Disease
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease
RBCs become hard, deoxygenated and crescent- or C-shaped in patients with haemoglobin polymerisation. Credit: Global Blood Therapeutics, Inc.
Learn more
Hover over the logos to learn more about the companies who made this project possible.
Close
-
SynapCon
SynapCon specialises in the development of innovative software solutions for...
About
SynapCon specialises in the development of innovative software solutions for clinical trial and medical research project management.
FollowMake an Enquiry
-
Pilloxa
Pilloxa creates digital and remote solutions to optimise clinical trials...
About
Pilloxa creates digital and remote solutions to optimise clinical trials and patient support programmes through supporting medical adherence and patient retention.
FollowMake an Enquiry
-
SOM Biotech
SOM Biotech is an Artificial Intelligence AI drug discovery and...
About
SOM Biotech is an Artificial Intelligence AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology.
FollowMake an Enquiry